NCT03374553已完成不适用
A Prospective, Open, Multicentre Clinical Trial Analysing the Effectiveness and Safety of MINIject 636 in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 4
- 主要终点
- Reduction in medicated diurnal IOP
研究概览
简要总结
The study will evaluate the efficacy and safety of MINIject 636 and IOP lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery. Overall, the patient will be asked to perform several examinations up to 24 months after surgery.
The primary efficacy objective of the present study is to show the IOP reduction under medication 6 months after surgery compared to medicated diurnal IOP at screening.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of primary or secondary open angle glaucoma during screening/baseline visit or earlier.
- •Grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45 degrees) according to Shaffer Angle Grading System.
- •Glaucoma not adequately controlled
排除标准
- •Diagnosis of glaucoma other than open angle glaucoma
- •Grade 2, grade 1 and grade 0 according to Shaffer Angle Grading System.
- •Neovascular glaucoma in the study eye
- •Prior glaucoma surgery in the study eye
- •Clinically significant corneal disease
- •Patients with poor vision
结局指标
主要结局
Reduction in medicated diurnal IOP
时间窗: 6 months after surgery
DODT/SODT arm will be evaluated separately
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
不适用
Effect of the MobiusHD® in Patients With Heart FailureHeart Failure With Reduced Ejection FractionNCT04590001Vascular Dynamics, Inc.50
尚未招募
不适用
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter StudyLeukemia, Lymphocytic, Acute, AdultNCT06649422Shandong University36
已完成
2 期
Three Months Treatment With SB683699 In Patients With Relapsing Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT00097331GlaxoSmithKline261
进行中（未招募）
1 期
A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic AsthmaAsthmaNCT05584306Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.24
已完成
2 期
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's DiseaseCrohn's DiseaseNCT00101946GlaxoSmithKline17